Notice about cookies

Close

This website uses a limited number of cookies to improve your browsing experience. For further information (including how to withdraw consent), please refer to our Cookie Policy. By clicking Accept below or continuing to use this website (including closing this message), you confirm that you have read and consent to our use of cookies as detailed in our Cookie Policy.

Accept

UCB's Global Corporate Website
Welcome to UCB in the United States

Categories

Archives

Apr

11

Our Leadership and Legacy in Epilepsy and Rare Syndromes

Read More Share:linkedin| twitter| email

Oct

04

UCB presents late-breaking posters at Child Neurology Society Meeting

Read More Share:linkedin| twitter| email

Apr

20

UCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual Meeting

Read More Share:linkedin| twitter| email

Apr

17

UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance

Read More Share:linkedin| twitter| email

Aug

22

A Caregiver’s Perspective: Returning to School This Fall

Read More Share:linkedin| twitter| email

Jun

13

UCB Builds Partnerships with Rare Epilepsy Syndrome Patient Groups

Read More Share:linkedin| twitter| email

May

02

JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA® (fenfluramine) Oral Solution in Lennox-Gastaut Syndrome (LGS)

Read More Share:linkedin| twitter| email

Apr

01

UCB Showcases Strength of Broad Neurology Portfolio at 74th American Academy of Neurology (AAN) Annual Meeting

Read More Share:linkedin| twitter| email

© 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
USPR-CORP-0115-00003(2)